Curasight
powered by Stokk.io

Q3 2023 Presentation

Mon, 27 Nov, 2023, 14:00 – 15:00
This event has ended. Sign up below to watch the recording.
Sign in to access all the features of the platform.

How does this Q&A work:

This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.

The company will address as many questions as possible, and focus on those questions most wanted by investors.

Speakers at this event:

Andreas Kjær
CSO & Founder
Ulrich Krasilnikoff
CEO

13 Questions

R
R**** *****
Nov. 27, 2023
Asked Live

Can you disclose a timline for the start of Phase 3 in Prostate and Glioblastoma?

Upvote
0 upvotes
Answered by   Andreas Kjær - CSO & Founder at Curasight
See answer
C
Casper Olsen
Nov. 10, 2023

In the presentation at Økonomisk Uge Brev in june 2023, there was a question about the liquidity of the stock. Management said that they might look into either a move to nasdaq in Sweden or possibly a dual listing?
Is there any new information about this?
Kind regards
Casper

Upvote
3 upvotes
Answered by   Ulrich Krasilnikoff - CEO at Curasight
See answer
A
A**** *****
Nov. 22, 2023

Previously in 2023 you have mentioned that you are looking on how to secure funding for next year, in the second half of this year. How is it going with that work and are you in talks with larger investors as well?

Upvote
2 upvotes
Answered by   Ulrich Krasilnikoff - CEO at Curasight , Ulrich Krasilnikoff - CEO at Curasight
See answer
J
J**** *****
Nov. 27, 2023

What do you expect the Stock value is in the end of 2024

Upvote
1 upvote
Answered by   Ulrich Krasilnikoff - CEO at Curasight , Andreas Kjær - CSO & Founder at Curasight
See answer
R
Ronnie Lind
Nov. 27, 2023

What are your plans for the indications in Lungcancer and Breastcancer?

Upvote
1 upvote
Answered by   Andreas Kjær - CSO & Founder at Curasight
See answer
A
A**** *****
Nov. 27, 2023

When do you expect the first payment from Curium?

Upvote
1 upvote
Answered by   Ulrich Krasilnikoff - CEO at Curasight
See answer
T
Tobias Westerskov
Nov. 26, 2023

RedEye talks about another phase2 trial in prostate cancer before moving to phase 3 - could you touch on this please?

Upvote
1 upvote
Answered by   Andreas Kjær - CSO & Founder at Curasight
See answer
F
Finn Tüchsen
Nov. 24, 2023

Please tell us what the status og the phase III study in prostate cancer is.

Upvote
1 upvote
Answered by   Andreas Kjær - CSO & Founder at Curasight
See answer
T
Tobias Westerskov
Nov. 23, 2023

Could you talk a bit about the posibility of expanding the current pipeline? Considering results in both breast and lung cancer.

Upvote
1 upvote
Answered by   Andreas Kjær - CSO & Founder at Curasight
See answer
I
Iskandar Hussain
Nov. 27, 2023

How long will patients need to be follow for uTreat?

Upvote
0 upvotes
Answered by   Andreas Kjær - CSO & Founder at Curasight
See answer
I
Iskandar Hussain
Nov. 27, 2023

How long will you need to follow patients for uTreat?

Upvote
0 upvotes
Answered by   Andreas Kjær - CSO & Founder at Curasight
See answer
R
R**** *****
Nov. 27, 2023

Do you plan for a combined study in Glioblastoma with both Utrace and Utreat and also same partner to support both Utrace and Utreat? And if so could this also be a strategy in other indications with a partner who covers both Utrace and Utreat in same indications?

Upvote
0 upvotes
Answered by   Andreas Kjær - CSO & Founder at Curasight
See answer
A
A**** *****
Nov. 27, 2023

Are you satsifed with the coverage from SEB?
Any plans of additional coverage from other major investment banks?

Upvote
0 upvotes
Answered by   Ulrich Krasilnikoff - CEO at Curasight
See answer